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South Africa is considered highly endemic for hepatitis A virus (HAV) although few seroprev-
alence studies have been conducted over the past two decades. The World Health Organi-
zation recommends integrating HAV vaccination into national childhood immunization
schedules where there is transition from high to intermediate endemicity. As a means of
gauging age-specific rates of infection, we report HAV seroprevalence rates among speci-
mens tested for HAV serology within South Africa’s public health sector from 2005–2015.
Materials and methods
Hepatitis A serology results (Anti-HAV IgM, IgG and total antibody) from 2005–2015 were
extracted from South Africa’s National Health Laboratory Service’s Corporate Data Ware-
house (NHLS CDW), the central data repository of all laboratory test-sets within the public
health sector. Results were extracted according to test-set, result, date of testing, health
facility, name, surname, age, and sex. Anti-HAV IgG results were merged with total antibody
results to reflect anti-HAV seroprevalence. Testing volume, positivity rates and age-specific
anti-HAV seroprevalence rates by year and geographic distribution are described.
Results and discussion
A total of 501 083 HAV IgM results were retrieved, of which 16 423 (3.3%) were positive,
484 259 (96.6%) negative and 401 (0.1%) equivocal; and 34 710 HAV total antibody/IgG
tests of which 30 675 (88.4%) were positive, 4 020 (11.6%) negative and 15 equivocal.
Whereas IgM positivity was highest among the 1–4 year age group (33.5%) and lowest
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among patients >45 years (<0.5%), total antibody positivity ranged from its lowest level of
52.7% in the 1–4 year age group increasing to levels of >90% only after 25 years of age.
Conclusion
Anti-HAV total antibody testing within the South African public health sector demonstrates
seroprevalence rates reach levels >90% only in adulthood, suggesting South Africa could
be in transition from high to intermediate endemicity. Prospective studies with geographi-
cally representative sampling are required to confirm these findings and evaluate provincial
and urban/rural heterogeneity.
Introduction
Hepatitis A viral (HAV) infection is the leading cause of viral hepatitis globally [1]. It is usually
transmitted via the faecal/oral route through ingestion of contaminated food or water.
Whereas exposure to HAV during early childhood is predominantly associated with asymp-
tomatic infection, older children and adults often experience symptomatic disease; with
increasing severity associated with increasing age.(1) Unlike hepatitis B or C viral infection,
HAV disease is usually self-limiting and not associated with chronicity, it is nevertheless asso-
ciated with considerable economic burden [2].
Anti-HAV antibodies usually appear a few weeks after infection, with both anti-HAV IgM
and IgG often present at the time of initial clinical presentation. Whereas IgM levels decline
over 3–6 months following infection, IgG usually persists conveying lifelong immunity. Either
anti-HAV total antibody or anti-HAV IgG testing can be performed to determine immunity
to hepatitis A infection, which occurs as a result of either natural infection or vaccination [3].
Hence, anti-HAV seroprevalence (presence of anti-HAV total antibody or anti-HAV IgG)
gives a measurement of susceptibility to new HAV infections and is a useful epidemiological
tool to investigate risk amongst different age groups within a population [4].
The World Health Organization (WHO) defines hepatitis A endemicity by anti-HAV age-
seroprevalence for a population. High endemicity being a seroprevalence of�90% by 10 years
of age, intermediate if seroprevalence is<90% by 10 years but�50% by 15 years of age, low if
seroprevalence is <50% by 15 years but�50% by 30 years of age, and very low if seropreva-
lence is<50% by 30 years of age [4]. In highly endemic countries large-scale vaccination pro-
grammes are deemed unnecessary as almost all persons are asymptomatically infected with
HAV during early childhood; thereby effectively preventing clinical hepatitis A in later life [4].
With a change from high to intermediate endemicity, however, the incidence of clinically
apparent hepatitis A increases, with countries in transition demonstrating HAV infection as a
leading cause of fulminant hepatic failure [4]. On account of this the WHO recommends HAV
vaccination be integrated into national immunization schedules for children in populations
where seroprevalence drops to<90% by 10 years of age [4]. In South Africa, HAV vaccination
is recommended within the private health sector, comprising part of the routine childhood
immunisation schedule. However, within the public health sector HAV vaccination is cur-
rently not part of the expanded programme on immunization. Hence, the presence of anti-
HAV total antibodies or IgG among individuals attending public health facilities is likely the
result of natural infection. If national seroprevalence patterns are found to reflect intermediate
endemicity across the general population, implementation of a national HAV vaccination pol-
icy may be considered.
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Several factors have been found to contribute to hepatitis A seroprevalence. In particular, a
rise in socioeconomic indicators, such as income, and an increase in access to clean water
strongly correlate with a decreased incidence of HAV infection and therefore lower age-sero-
prevalence rates, especially among children [5,6]. Southern Africa is considered to have high
endemicity for hepatitis A with seroprevalence among children aged 1–4 years and 5–9 years
estimated to be 83% and 92% respectively [7]. Furthermore, it is thought that the region has
remained highly endemic for HAV for the years 1990 to 2005 [7]. Although the true burden of
HAV disease is currently unknown, previous serological studies from South Africa have dem-
onstrated that variables associated with higher-socioeconomic status were significantly associ-
ated with increased susceptibility to symptomatic HAV infection [8–10]. Whereas South
Africa has undergone significant social transformation over the past two decades, with 92.5%
of households now having access to clean drinking water and adequate sanitation facilities,
increasing from 62.3% in 2002 [11], it remains to be determined whether South Africa has
transitioned to a level of intermediate HAV endemicity. We report the HAV seroprevalence
rates among specimens submitted for HAV testing between 2005 and 2015 within South Afri-
ca’s public health sector.
Materials and methods
This was a cross-sectional descriptive study of routine laboratory data from the South African
public health sector from 2005 to 2015. All anti-HAV serology results (IgM, IgG and total anti-
body) were extracted from the National Health Laboratory Service’s Corporate Data Ware-
house (NHLS CDW), the central data repository of laboratory results within the public health
sector in South Africa. Results were extracted according to test-set, qualitative result, date of
testing, health facility, and patient demographic details, including name, surname, age, and
sex. Each test episode was assigned a unique numerical identifier generated from the patient
demographic details after which patient name and surname were deleted prior to analysis.
Criteria for inclusion in the study were results for anti-HAV IgM, anti-HAV IgG and anti-
HAV total antibody that were requested within the NHLS between 01 January 2005 to 31
December 2015. Test-sets with a verified positive, equivocal and negative result were included
in the analysis (equivocal results refer to valid results that are neither positive nor negative,
and are interpreted as such according to the assay manufacturer’s package insert). Test-sets
registered without a qualitative result, tests registered for occupational health and safety or
study purposes, and duplicate records were excluded from the analysis.
Data were extracted from the NHLS CDW as a Microsoft Excel spreadsheet, and imported
into Stata 14 (StataCorp, Texas, USA) for descriptive analysis. All anti-HAV IgG results were
merged with anti-HAV total antibody results to reflect HAV exposure (natural- or vaccine-
derived) in patients. As testing to determine HAV immunity was predominantly performed using
total anti-HAV antibody assays, we have referred to both of these tests as total antibody testing.
To determine acute HAV infection, anti-HAV IgM assays are routinely used within the NHLS.
Anti-HAV IgM and total antibody testing patterns and positivity rates were calculated by
age group and province. Positivity rates were calculated as the proportion of positive results
over total tested. Results were described per year of testing as well as aggregated for all tests
resulted between 2005 and 2015. The annual number of acute HAV cases diagnosed per 100
000 population was calculated per province and nationally, rounded-off to the nearest whole
number, using population data from Statistics South Africa.
Permission to access and analyse the data was obtained from the NHLS and ethical clear-
ance was obtained from the Human Research Ethics Committee of the University of the Wit-
watersrand (M160667).
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Results
From 1 January 2005 to 31 December 2015 a total 523 393 specimens registered for HAV serol-
ogy were retrieved from the NHLS data warehouse. Of the 520 847 registered specimens that
met the inclusion criteria, 501 083 were anti-HAV IgM results (459 992 with a registered age
or date of birth) and 34 710 anti-HAV total antibody results (31 160 with a registered age or
date of birth). A total of 14 946 specimens had both anti-HAV IgM and total antibody test
results.
Laboratory confirmed acute hepatitis A
Among anti-HAV IgM results, 16 423 (3.3%) were positive, 484 259 (96.6%) were negative,
and 401 (0.1%) were equivocal. Among patients with a positive result whose sex was registered
within the laboratory information system, 53.0% were male and 47.0% were female (sex was
unknown in 1.4% of cases), with 4% of males testing positive compared with 2.7% of females.
Two thirds of all laboratory confirmed acute hepatitis A cases (anti-HAV IgM positive)
occurred among children <15 years of age, with 25% of laboratory confirmed infections diag-
nosed among children 1–4 years of age. Excluding infants <1 year of age, who acquire tran-
sient immunity due to the passive transfer of maternal antibodies in-utero, older age was
associated with a decline in the positivity rate, from its highest level of 33.9% in the 1–4 years
age group to levels of�0.5% in the�40 year age groups, with an overall positivity rate of 3.3%
among all specimens tested. Laboratory confirmed acute HAV cases with a documented age /
DOB, and testing patterns per age range are shown in Table 1.
Between 2005 and 2015, the year with the least number of IgM positive results was 2006,
with 715 patients diagnosed with acute hepatitis A, and the year with the greatest number was
2014, with 2 779 patients diagnosed. However, despite the increase in the number of confirmed
hepatitis A cases, the positivity rate declined from 8.4% to 2.5% associated with an increase in
the annual volume of testing during this period, from 10 096 anti-HAV IgM tests in 2005 to 89
297 in 2015. The 30–39 year age group had the largest IgM testing volume (116 828 results)
with a positivity rate of 0.8% (Fig 1). Whereas only 15% of IgM testing was performed among
patients <20 years of age, 75% of all positive results occurred in this age group. Restricting
analysis to patients <10 years of age, which accounted for 50% of all laboratory confirmed
Table 1. Laboratory confirmed acute Hepatitis A cases (with a documented age / DOB) and testing patterns per year-age range, 2005–2015.








<1 7 (1.8%) 9 828 (2.2%) 115 (0.8%) 9 950 (2.2%)
1–4 70 (17.9%) 7 423 (1.7%) 3 838 (25.0%) 11 331 (2.5%)
5–9 49 (12.5%) 8 280 (1.9%) 3 654 (23.8%) 11 983 (2.6%)
10–14 32 (8.2%) 10 118 (2.3%) 2 265 (14.8%) 12 415 (2.7%)
15–19 39 (10.0%) 21 909 (4.9%) 1 531 (10.0%) 23 479 (5.1%)
20–24 31 (7.9%) 42 501 (9.6%) 1 389 (9.1%) 43 921 (9.6%)
25–29 25 (6.4%) 59 774 (13.5%) 890 (5.8%) 60 689 (13.2%)
30–39 46 (11.7%) 115 896 (26.1%) 886 (5.8%) 116 828 (25.4%)
40–49 35 (8.9%) 77 030 (17.3%) 412 (2.7%) 77 477 (16.8%)
50–59 23 (5.9%) 49 110 (11.1%) 197 (1.3%) 49 330 (10.7%)
60–69 20 (5.1%) 26 538 (6.0%) 100 (0.7%) 26 658 (5.8%)
70–79 12 (3.1%) 11 719 (2.6%) 52 (0.3%) 11 783 (2.6%)
�80 3 (0.8%) 4 120 (0.9%) 25 (0.2%) 4 148 (0.9%)
Total (%, n/N) 392 (0.1%) 444 246 (96.6%) 15 354 (3.3%) 459 992 (100.0%)
https://doi.org/10.1371/journal.pone.0216033.t001
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acute hepatitis A cases in the country, an overall decrease in the positivity rate can be appreci-
ated despite increases in the total number of children diagnosed with acute HAV annually
(Fig 2).
Considerable variation in anti-HAV IgM testing volumes and positivity rates were observed
among South Africa’s nine provinces over the 11-year period for which data was analysed.
Among the 500 948 results registered by province, KwaZulu-Natal (187 171) followed by Gau-
teng (107 446) and the Western Cape (56 952) had the highest number of anti-HAV IgM tests,
with the Western Cape having the greatest number of positive results and highest positivity
rate (4 217 and 7.4%, respectively), followed by 4 147 (3.9%) in Gauteng and 3 947 (2.1%) in
KwaZulu-Natal (Table 2). These three provinces accounted for 75% of all laboratory diagnosed
acute hepatitis A cases in the country.
In 2014, the year with the highest number of HAV cases diagnosed equivalent to 5 cases per
100 000 of the national population, KwaZulu-Natal had an estimated 10 cases, Western Cape 9
cases, Free-State, Limpopo, Mpumalanga, North-West and Northern Cape provinces each had
3 cases, and Gauteng 2 cases per 100 000 population.
Hepatitis A immunity
Of the specimens tested for anti-HAV total antibody, 30 675 (88.4%) were positive, 4 020
(11.6%) negative and 15 equivocal. Test episodes with an anti-HAV total antibody negative
result and a documented sex showed 54.1% were male and 45.9% were female (0.9% of cases
sex was unknown). Excluding infants <1 year of age, older age was associated with an increase
in seropositivity, with the positivity rate ranging from its lowest level of 52.7% in the 1–4 year
age group to levels >90% in the>25 year age groups. Anti-HAV seropositive cases and rates
among different age groups for the study period are illustrated in Table 3. Fig 3 represents age
as a continuous variable and allows visualization of HAV seroprevalence alongside the acute
Fig 1. The proportion of laboratory confirmed acute Hepatitis A infections of anti-HAV IgM tests requested per age group, 2005–2015.
https://doi.org/10.1371/journal.pone.0216033.g001
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hepatitis A positivity rate. A seropositive rate of 90% was reached only well after 10 years of
age.
Both anti-HAV total antibody and anti-HAV IgM tests were requested in 14 946 patients
during the study period. Cross tabulation of the results, as illustrated in Table 4, show that 643
(4.3%) of those tested for anti-HAV total antibodies had an acute HAV infection.
The volume of anti-HAV total antibody tests increased from 804 in 2005, peaking at 10 758
tests in 2011, and thereafter declining to 1 694 in 2015. Both the number and proportion of
positive total antibody results increased with the number of tests performed, ranging from 554
(68.8%) in 2005, to a peak of 10 057 (93.5%) in 2011, and thereafter declining to 1 513 (89.3%)
in 2015 (Table 3).
Fig 2. Laboratory confirmed acute Hepatitis A infection among children aged<10 years, 2005–2015.
https://doi.org/10.1371/journal.pone.0216033.g002









Eastern Cape 43 (10.7%) 54 202 (11.2%) 895 (5.5%) 55 140 (11.0%)
Free State 19 (4.7%) 25 658 (5.3%) 1 149 (7.0%) 26 826 (5.4%)
Gauteng 120 (29.9%) 103 179 (21.3%) 4 147 (25.3%) 107 446 (21.5%)
KwaZulu-Natal 1 (0.3%) 183 223(37.8%) 3 947 (24.0%) 187 171 (37.4%)
Limpopo 4 (1.0%) 23 608 (4.9%) 858 (5.2% 24 470 (4.9%)
Mpumalanga 2 (0.5%) 21 037 (4.3%) 683 (4.2%) 21 722 (4.3%)
North West 22 (5.5%) 18 235 (3.8%) 436 (2.7%) 18 693 (3.7%)
Northern Cape 2 (0.5%) 2 442 (0.5%) 84 (0.5%) 2 528 (0.5%)
Western Cape 188 (46.9%) 52 547 (10.9%) 4 217 (25.7%) 56 952 (11.37%)
Grand Total 401 (0.1%) 484 131 (96.6%) 16 416 (3.3%) 500 948 (100%)
https://doi.org/10.1371/journal.pone.0216033.t002
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Provincial variation in anti-HAV total antibody testing were also observed, with the major-
ity of tests performed in the Western Cape, KwaZulu-Natal and Gauteng (Table 5). Among
these three provinces anti-HAV total antibody seropositivity was highest in KwaZulu-Natal
(95.8%), then Western Cape (86.1%) and Gauteng (64.5%) (Table 4).
Table 3. Hepatitis A seropositive cases (%) by age-range and year, 2005–2015.
Year Age (years)











































































































































































































































































































































Seropositivity (%) within age-range �90% �75-<90% �50-<75% <50%
https://doi.org/10.1371/journal.pone.0216033.t003
Fig 3. Hepatitis A age-seroprevalence among patients tested within the South African public sector, 2005–2015. IgM, anti-Hepatitis A IgM antibody positivity;
Total AB, anti-Hepatitis A total antibody positivity.
https://doi.org/10.1371/journal.pone.0216033.g003
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Discussion
This study represents the largest description of HAV seroprevalence within South Africa to
date. Using routine laboratory data, hepatitis A testing patterns, acute infection and seroposi-
tivity rates within the public health sector are described and the level of endemicity gauged.
Although previous studies from southern Africa have described the region as highly
endemic for HAV, routine laboratory data presented here suggest South Africa has a level of
intermediate endemicity with anti-HAV seroprevalence reaching a level of>90% only among
adults>25 years of age. These findings are in keeping with the last published serological survey
conducted in South Africa which reported seropositivity of 80% among children 11–13 years
of age from low socio-economic groups (and a much lower seroprevalence among children
from affluent backgrounds) [10]. Unfortunately, we were unable to accurately determine
yearly seroprevalence trends, despite data obtained from 2005 to 2015, on account of the rela-
tive low volume of anti-HAV total antibody testing and uneven distribution of testing among
the various age groups. Nevertheless, aggregated data over the 11-year period portrays a com-
pelling picture whereby total antibody seroprevalence and IgM positivity follow opposite tra-
jectories during childhood, both of which plateau at around 25 years of age, reflecting minimal
infection once immunity reaches levels of>90%. Although the volume of anti-HAV IgM test-
ing performed among adults was found to increase over the years, and was associated with a
marked reduction in percentage positivity, the number of laboratory confirmed acute hepatitis
A cases has increased considerably each year, by a factor of three, over the past decade.
Whereas 1 612 cases of Hepatitis A were notified between the years 2001 and 2005, more cases
were diagnosed in 2015 alone highlighting the need for better electronic notification systems
as well as raising concerns regarding the potential increase in symptomatic acute infection.
Symptomatic illness from HAV infection is directly related to age, with 70% of pre-school
children having no symptoms whereas >70% of infected adults present with jaundice [12].
Table 4. Cross tabulation of test-sets where both anti-HAV total antibody and anti-HAV IgM tests were requested, 2005–2015.
Anti-HAV IgM antibodies Anti-HAV total antibodies
Negative Positive Equivocal Total
Negative 1 039 13 230 2 14 271
Positive 33 614 0 647
Equivocal 0 28 0 28
Total 1 072 13 872 2 14 946
https://doi.org/10.1371/journal.pone.0216033.t004









Eastern Cape 2 (13.3%) 88 (2.2%) 2 126 (6.9%) 2 216 (6.4%)
Free State 2 (13.3%) 96 (2.4%) 486 (1.6%) 584 (1.7%)
Gauteng 0 (0.0%) 1 000 (24.9%) 1 825 (6%) 2 825 (8.1%)
KwaZulu-Natal 0 (0.0%) 567 (14.1%) 13 232 (43.2%) 13 799 (39.8%)
Limpopo 0 (0.0%) 54 (1.4%) 36 (0.1%) 90 (0.3%)
Mpumalanga 0 (0.0%) 38 (0.9%) 6 (0%) 44 (0.1%)
North West 0 (0.0%) 87 (2.2%) 52 (0.2%) 139 (0.4%)
Northern Cape 0 (0.0%) 18 (0.4%) 68 (0.2%) 86 (0.3%)
Western Cape 11 (73.4%) 2 070 (51.5%) 12 827 (41.8%) 14 908 (42.9%)
Grand Total 15 (0.04%) 4 018 (11.60%) 30 658 (88.36%) 34 691 (100%)
https://doi.org/10.1371/journal.pone.0216033.t005
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Hence, HAV infection among young children is expected to be under-reported. Yet despite
this, routine laboratory data suggests that children 1–4 years of age comprised the highest pro-
portion (33.5%) of acute hepatitis A cases compared to all other age groups. Furthermore, the
data suggest that in contrast to children, adults with symptoms of hepatitis are unlikely to have
hepatitis A infection within the South African context, with <0.5% of those aged>45 years
testing positive yet comprising a quarter of all IgM tests performed. We suggest that com-
monly used algorithms for serological diagnosis of viral hepatitis should be reviewed to ensure
age-appropriate hepatitis serology testing which in turn will lead to appropriate and cost-effec-
tive laboratory utilization [13–14]. Hence, clinical requests for ‘viral hepatitis testing’ should
not routinely include HAV IgM testing for all patients. These findings lay groundwork for fur-
ther investigation to determine age-specific seroprevalence rates among healthy individuals,
especially children and adolescent age groups, within South Africa.
Inter-provincial variations were seen with both acute hepatitis A cases and seroprevalence.
However, on account of variations in access to testing, different clinical testing algorithms and
incomplete data within the data warehouse it is not possible to accurately determine geo-
graphic differences in incidence of HAV infection using routine laboratory data. The fact that
the Western Cape was the province with the highest number and proportion of IgM positive
tests and had a relatively low overall anti-HAV seroprevalence rate suggests inter-provincial
differences are likely to exist and should be taken into consideration when planning prospec-
tive seroprevalence studies.
Limitations
A number of important limitations exist regarding this study. Data from NHLS CDW was
used which reflects testing practices within the South African public health sector only. This
analysis may therefore not necessarily reflect the population as a whole as more affluent sectors
of South African society would not have been included. Approximately 20% of the South Afri-
can population engage with the private health sector [15], and this component of the popula-
tion is likely to have a much lower infection rate as a result of private vaccination practice and
better living conditions. When infection does occur within the private sector, it is likely to
arise at an older age with a greater proportion of infections associated with symptomatic dis-
ease. It is important to note that clinical data, including patient socio-economic status, is not
captured within the NHLS CDW thereby precluding a description of these variables and their
association with HAV seroprevalence within the South African public health sector.
As testing for anti-HAV IgM is usually performed within the clinical context of acute hepa-
titis, it can be assumed that the overwhelming majority of patients tested for IgM had pre-
sented with clinical disease. Reasons for testing anti-HAV total antibody, however, are much
less clear with 60% of anti-HAV total antibody testing performed without simultaneous IgM
testing. Hence, seroprevalence findings from routine laboratory data may not be representative
of the general population. An additional limitation relates to the assays used, for which data
was not extracted. Various different HAV serological assays are used within the NHLS,
although it is understood that all HAV serology assays used are approved for in-vitro diagnos-
tic use.
Although increase in HAV IgM testing volume likely reflects increased access to healthcare
between the years 2005 to 2015, data was incomplete for KwaZulu-Natal province prior to
2010 and therefore does not reflect the total number of test-sets within the public sector.
Lastly, on account of transcription errors, linking of results and de-duplicating results for
individual patients using probabilistic matching of demographics has flaws; the patient
Hepatitis A virus seroprevalence in South Africa, 2005-2015
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linking-algorithm used in this study has a reported sensitivity of 73% for patient-linkages with
83% of matches correctly linking test results to the same patient [16].
Conclusions
Among patients tested within South Africa’s public health sector from 2005 to 2015, acute hep-
atitis A cases occurred mostly amongst children <15 years of age with few cases occurring
among adults despite considerable testing. Anti-HAV total antibody results demonstrate that
seroprevalence rates reach levels >90% only during adulthood among individuals aged>25
years, suggesting South Africa is a country of intermediate endemicity. The very low percent-
age positivity of anti-HAV IgM results among adults aged>35 years suggest that this test is
not essential as a first line screening tool for adults with suspected acute hepatitis. Further sero-
prevalence studies using representative population-based samples are needed to confirm these
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